Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more


follow us on twitter


Publications

Enterprise Annual Review 2012/2013
Whether it’s our working with corporations and assisting student entrepreneurs or spinning out research, I hope that you enjoy reading about all our enterprise activities from across the university in our Annual Review 2012/2013.

Prof Stephen Caddick
Vice-Provost (Enterprise)

Enterprise Annual Review 2011/2012
It’s been an excellent start to the five-year plan for Enterprise and you can read more in this review. But such is the strength, depth and diversity of our activities that it can only reflect a small proportion of the outstanding work of the UCL community. Every member of UCL is to be congratulated for a tremendously successful year and with the promise of much, much more to come.

Prof Stephen Caddick
Vice-Provost (Enterprise)

Enterprise Strategy 2011 - 2015
Following the publication of the UCL Enterprise Strategy in 2011, many people have been struck by the significance of the UCL commitment to supporting the development of 500 new businesses over the next five years.